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37340 | RSC Adv., 2017, 7, 37340–3734of photoactivatable metallodrugs:
photonic crystal ﬁbre microﬂow reactor coupled to
ESI mass spectrometry†
Ruth J. McQuitty, a Sarah Unterkoﬂer, b Tijmen G. Euser, bc
Philip St.J. Russell *b and Peter J. Sadler *a
We explore the eﬃcacy of a hyphenated photonic crystal ﬁbre microﬂow reactor – high-resolution mass
spectrometer system as a method for screening the activity of potential new photoactivatable drugs. The
use of light to activate drugs is an area of current development as it oﬀers the possibility of reduced side
eﬀects due to improved spatial and temporal targeting and novel mechanisms of anticancer activity. The
di-nuclear ruthenium complex [{(h6-indan)RuCl}2(m-2,3-dpp)](PF6)2, previously studied by Magennis et al.
(Inorg. Chem., 2007, 46, 5059) is used as a model drug to compare the system to standard irradiation
techniques. The photodecomposition pathways using blue light radiation are the same for PCF and
conventional cuvette methods. Reactions in the presence of small biomolecules 50-guanosine
monophosphate (50-GMP), 50-adenosine monophosphate (50-AMP), L-cysteine (L-Cys) and glutathione
(g-L-glutamyl-L-cysteinyl-glycine, GSH) were studied. The complex was found to bind to nucleobases in
the dark and this binding increased upon irradiation with 488 nm light, forming the adducts [(h6-indan)
Ru2(m-2,3-dpp) + 50-GMP]
2+ and [(h6-indan)Ru + (50-AMP)]+. These ﬁndings are consistent with studies
using conventional methods. The dinuclear complex also binds strongly to GSH after irradiation,
a possible explanation for its lack of potency in cell line testing. The use of the PCF-MS system
dramatically reduced the sample volume required and reduced the irradiation time by four orders of
magnitude from 14 hours to 12 seconds. However, the reduced sample volume also results in a reduced
MS signal intensity. The dead time of the combined system is 15 min, limited by the intrinsic dead
volume of the HR-MS.Introduction
The use of light activated drugs in the form of photodynamic
therapy (PDT) is well established in the clinic, having gained
FDA approval in the US in 1995.1 Photodynamic therapy
involves the use of a photosensitiser that is irradiated with light,
normally within the ‘phototherapeutic window’ of 650–850 nm.
The excited photosensitiser then generates reactive oxygen
species, especially 1O2, which cause irreparable damage to the
tumour cell and induce cell death.2 Although a proven treat-
ment, PDT does have its limitations, such as photosensitivity of
the patient aer treatment and the reliance of the treatment onarwick, Gibbet Hill Road, Coventry CV7
ght, Staudtstrasse 2, D-91058 Erlangen,
e
ry, J J Thomson Avenue, Cambridge CB3
tion (ESI) available. See DOI:
8the presence of oxygen, which means that its eﬃcacy is curbed
in the hypoxic regions of solid tumours.3
The search for improved photoactive drugs with a wider
spectrum of activity and that possess a mechanism of action
independent of the presence of oxygen has led to many new
photoactive agents being synthesised. Some of these make use
of the unique photochemistry of inorganic compounds, utilis-
ing a range of metal centres such as iridium,4 ruthenium,5
platinum,6 and dinuclear mixed-metal complexes.7–10 Examples
from our own work include photoactivatable diazido Pt(IV)
complexes,11 and organometallic Ru(II) compounds.12,13 This
work has resulted in promising drug candidates, such as
trans,trans,trans-[Pt(py)2(N3)2(OH)2] which is active at micro-
molar concentrations against a range of cancer cell lines when
irradiated with low doses of blue light.14
Since the chemistry of electronically-excited states of pho-
toactive metal complexes diﬀers from that of the ground state,
photoproducts are likely to be produced which can aﬀect
cellular biochemical pathways in novel ways.15 Such behaviour
may be advantageous for avoiding cross-resistance with existing
drugs. For example, combatting resistance to current platinum
drugs is an important clinical problem.16 Hence there is a needThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineto devise methods for analysis of the photodecomposition
pathways of photochemotherapeutic agents on a wide range of
timescales. Conventional methods oen involve the separate
irradiation and subsequent analysis of a photoactive compound
in solution, require relatively high sample volumes (at least 600
mL), and can involve lengthy sample handling procedures. The
aim of the current work is to utilise the unique properties of
liquid-lled hollow-core photonic crystal bres (HC-PCFs) to act
as micro ow-reactors for the eﬃcient activation and analysis of
photoactivatable drugs on a much shorter timescale than is
possible with conventional methods.
HC-PCFs are bres constructed from silica, comprising
a 20 mm-sized hollow core channel, surrounded by a regular
two-dimensional arrangement of smaller channels (total
diameter ca. 200 mm),17 see Fig. 1B. The HC-PCF design, such as
the core size, the cladding pitch, and the thickness of the glass
webs surrounding the hollow core, can be adjusted such that
a desired range of wavelengths is guided along the core with
negligible losses.18–20 The same guiding mechanism, though
over a shied wavelength range, applies when the microstruc-
ture is lled with a liquid,21,22 meaning that light can propagate
in well-dened optical modes along a microscale microuidic
channel, as shown in Fig. 1B.
Such optouidic HC-PCFs are outstanding photochemical
microreactors, that outperform on-chip optouidic wave-
guides23,24 in several ways.25,26 First of all, the reaction volume
per cm interaction length is reduced to a few nL cm1 enabling
studies onminute sample volumes. In terms of photochemistry,
the available optical power P is conned to the small cross-
sectional area of the core (Acore  300  1012 m2), resulting
in a ve orders of magnitude larger average irradiance (I ¼ P/Fig. 1 (A) Structure of 1, [{(h6-indan)RuCl}2(m-2,3-dpp)](PF6)2. (B) Scann
correspond to fused silica glass and black areas correspond to holes, w
image is the optical mode at 488 nm wavelength, measured by a CC
optoﬂuidic interface mounts (see D) are used to couple light into the op
mount, accommodating an oﬀ-the-shelf straight-channel optoﬂuidic ch
This journal is © The Royal Society of Chemistry 2017Acore), as compared to a standard size cuvette irradiated by
a free-space beam. As a result, much lower laser powers are
required to achieve the same excitation conditions. Finally, HC-
PCF allows long optical path lengths that can be exploited for
enhanced detection sensitivity. Additional advantages are that
HC-PCFs are easily fabricated by established procedures27 from
high-quality fused silica glass, featuring negligible scattering
and absorbance in the UV-Vis range, as well as chemical
inertness.
Recent experimental studies have proven the eﬃcacy of
optouidic PCFs as eﬃcient photochemical reactors. Using
simultaneous in-bre absorption spectroscopy on a xed, static
sample volume, eﬃcient photoconversion of low quantum yield
reactions,25 photo-induced homogeneous catalysis,28 and
monitoring of the reaction kinetics of photoswitchable dyes
with sub-picomole sensitivity have been successfully demon-
strated.29 Cubillas et al. have published a comprehensive review
of the uses of PCFs for photochemistry and sensing
applications.30
The analysis of photodecomposition pathways in HC-PCFs
usually relies on absorption spectroscopy within the bre
core. While providing some useful in situ information, an
important limitation is that it is very diﬃcult to deduce struc-
tural information of reaction products from the absorption
spectrum alone. For this reason, we have recently combined
a continuous-ow HC-PCF microreactor with non-optical anal-
ysis methods to characterise unknown species more fully. A
piece of optouidic HC-PCF was interfaced with a low-volume
microuidic circuit, enabling photochemical reaction prod-
ucts to be fed directly into a mass spectrometer (MS),31 see
Fig. 1D. As a proof-of-principle, the well-known photoaquationing electron micrograph of the kagome´-lattice HC-PCF. Grey areas
hich in our experiment are ﬁlled with sample solution. The overlayed
D camera. (C) Photograph of the experimental setup. Custom-made
toﬂuidic PCF ﬂow reactor. (D) Photograph of one optoﬂuidic interface
ip.
RSC Adv., 2017, 7, 37340–37348 | 37341
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View Article Onlinereaction of cyanocobalamin (vitamin B12) to aquacobalamin
was studied and found to be in excellent agreement with
conventional irradiation methods.32 Importantly, the amount of
sample required was reduced 50 times when compared to the
conventional batch procedure using a cuvette.
In this study, we apply this novel optouidic system to gain
new insight into the properties of potential photoactivatable
drugs. The ruthenium complex 1, shown in Fig. 1A, is a dinu-
clear complex previously studied by Magennis et al.33 Upon
irradiation, 1 was found to lose an indane ligand and bind to
DNA. The complex can also undergo aquation in aqueous
solution in the dark, resulting in the loss of the chlorido
ligands. We have studied he photoactivation of 1 in the pres-
ence of a range of biomolecules as a guide to its possible
intracellular behaviour.
Experimental section
Materials
All water used was doubly deionised water (DDW), puried
using a Multipore Milli Q and a USF Elga UHQ water deionisers.
Microuidic mounts were constructed in-house at the Max
Planck Institute for the Science of Light in Erlangen. The
microuidic chips were purchased from microuidic Chip-
Shop. For sample introduction, a 500 mL-glass syringe from
Hamilton was used and a syringe pump from kdScientic.
Sodium salt 50-GMP (99.99%) and L-cysteine (99.99%) were
purchased from Sigma Aldrich. Both the 50-AMP (99.99%) and
glutathione (GSH, 99.99%) were purchased from Acros
Organics. Complex 1 ([{(h6-indan)RuCl}2(m-2,3-dpp)](PF6)2) was
synthesised according to the literature method.33
Sample preparation
All MS samples were ltered using NALGENE 0.2 mm PES lters
and then centrifuged at 14 000 rpm, 5 C for 10 min. The pH of
samples was measured using a Mettler-Toledo glass micro-
electrode connected to a Martini instruments Mi150 pH/
temperature bench meter calibrated at pH 4, 7 and 10 using
pH buﬀers from Mettler-Toledo.
Mass spectrometry
All mass spectra were obtained on a Bruker MaXis high-
resolution mass spectrometer (HR-MS). Samples were intro-
duced to the MS at a ow rate of 100 mL h1. The acquisition
parameters for spectra obtained in the positive mode were as
follows: scan range 50–3000 m/z, set capillary 3000 V, end plate
oﬀ-set 500 V, nebuliser pressure 0.4 bar, dry heater 180 C,
and dry gas 4.0 L min1. All spectra were processed using
Bruker Daltonics Analysis soware and Origin Pro 8.1.
Optouidic setup
A photograph of the optouidic photochemical microow
reactor is shown in Fig. 1C and D. Details of the implementa-
tion, especially of the optouidic interface between the optical
bre facets and the microuidic circuitry (PEEK tubing equip-
ment by VICI and Upchurch Scientic) via oﬀ-the-shelf37342 | RSC Adv., 2017, 7, 37340–37348microuidic chips (microuidic ChipShop), can be found in
Unterkoer et al.31 The HC-PCF used in the experiments was a L
z 15 cm long kagome´-type HC-PCF20 with a core diameter of
19.7 mm (Fig. 1A). This corresponds to a bre-dead volume of
1.4 mL in the cladding holes and 50 nL in the optouidic
core. The bre guides blue light (488 nm) in a well-dened
optical mode (see Fig. 1B) with waveguide loss of 3.5 dB m1,
meaning that the transmission losses through the 15 cm long
bre are below 12%. The inner diameter (100 mm) and length
(60 cm) of the PEEK tubing connecting the microuidic chip
with the MS, were kept short to minimise the dead volume of
the set-up. In this way, the dead volume of the circuitry between
bre exit and mass spectrometer was kept below 10 mL. A
continuous ow rate of 4tot ¼ 100 mL h1 ¼ 27.7 nL s1, was
established using a syringe pump. The ow rate was continu-
ously monitored with an inline microow meter (Sensirion
model SLG1430-150) placed just before the mass spectrometer.
The total sample volume ow through the bre consists of
a portion owing through the illuminated region in the core,
4core, and of a portion owing through the dark cladding holes,
4cladd. By application of Hagen–Poiseuille's law for laminar ow
in a parallel circuit of tubes we nd 4cladd¼ 5.64core for the bre
used. This gave rise to a ow velocity of 1.25 cm s1 through the
bre core and hence to a sample transit time through the core
strans of 12 seconds. This, combined with the dead volume of
the rest of the system gives and overall dead time of 6 min.
However, the time between sample introduction and observa-
tion of a stable mass spectrum was found to be in the order of
15min. This is likely due to the intrinsic dead volume of the HR-
MS itself and the time needed for the spray to stabilise.Irradiation
The photochemical conversion rate depends both on external
factors as well as on intrinsic parameters relating to the molecule
itself. Molecule-intrinsic parameters are characterised by the
molar extinction coeﬃcient 3, and the quantum yield F, i.e. the
fraction of absorbed photons that lead to the desired reaction. At
an excitation wavelength of 488 nm, 3¼ 1880 M1 cm1 and F¼
104 for complex 1.33 External factors are the excitation wave-
length l and the laser power P, which is directly proportional to
the irradiance I via I ¼ P/Acore. The light source used here was
a blue 488 nm laser from Toptica photonics. Prior to each indi-
vidual experiment, the laser power was adjusted such that full
photochemical conversion was achieved in the core, 1 C(strans)/
C0/ 1 (for details see ref. 26). Thismodel takes also into account
the length of the bre and the fraction of light launched into the
bre core, which varied from 50 to 75% between experimental
runs. Required powers P0 were calculated to be between
8–10 mW for the experiments discussed below, leading to
irradiances I0 on the order of 2400–3000 W cm
2, much larger
than can be achieved in conventional cuvette-based methods.Results and discussion
The photoactive dinuclear organometallic complex 1, [{(h6-
indan)RuCl}2(m-2,3-dpp)](PF6)2 (Fig. 1A), was selected for studyThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineby PCF-coupled-MS. The photoactivation, aquation and plasmid
DNA binding properties of this compound have been reported,33
and provide a basis for the reactions investigated here. The aim
of this series of experiments was to use the PCF as a micro-
reactor to photoactivate 1 in the presence of a range of small
biomolecules that are relevant to possible reactions in cells.
Upon irradiation, 1 loses an indane ligand and can bind to
DNA.33 The complex can also undergo aquation in aqueous
solution in the dark. Aquation can be prevented by the presence
of a high concentration of Cl ions. However, this approach is
impractical, as the mass spectrometer does not tolerate high
levels of salt. There were controls using conventional methodsFig. 2 (A and B) Direct infusion of solutions of 1, 250 mM in DDW. Peak a
(with inset of isotopic pattern), 888.96m/z [M + (PF6)]
+, and at 489.01m/
in DDW irradiated at 488 nm light (5 mW) for 14 h, in a cuvette showing t
dpp)]2+, 276.99m/z assignable to [(h6-indan)Ru2(m-2,3-dpp)]
2+. (C and D
dark; peaks assigned 372.0m/z as [M]2+, 888.96m/z as [M + (PF6)]
+ and f
of irradiation at 488 nm in the HC-PCF ﬂow reactor, the new peaks at 2
pattern) and at 276.99 m/z is assigned to [(h6-indan)Ru2(m-2,3-dpp)]
2+.
This journal is © The Royal Society of Chemistry 2017for each experiment and dark controls using both techniques.
Since data from both the PCF and the conventional methods
were acquired over time from aqueous solutions, account has to
be taken of the possible aquation of 1 in both dark and irradi-
ated samples.
The direct infusion (non-irradiated) controls, Fig. 2A, indi-
cate that the fragmentation process for this molecule is
diﬀerent from its photodissociation and aquation pathways.
Complex 1 and its products have complicated isotopic patterns;
therefore all of the m/z values reported refer to the mono-
isotopic peak for clarity. The main ions detected in the mass
spectrum from dark solutions are the doubly-chargedmolecularssignments in spectrum (A) of the solution in the dark 372.0 m/z [M]2+
z fragment ion [(h6-indan)RuCl(m-2,3-dpp)]+. Spectrum (B) of 1 250 mM
he appearance of a peaks at 227.04m/z assigned to [(h6-indan)Ru(2,3-
) PCF-MS system mass spectra of 250 mM 1 in DDW: (C) solution in the
ragment ion at 489.01m/z ([(h6-indan)RuCl(m-2,3-dpp)]+); (D) after 12 s
27.04 m/z assigned to [(h6-indan)Ru(2,3-dpp)]2+ (with inset of isotopic
RSC Adv., 2017, 7, 37340–37348 | 37343
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View Article Onlineion at 372.0m/z ([M]2+), a singly-charged PF6 adduct at 888.96m/
z ([M + (PF6)]
+) and a singly-charged fragment ion at 489.01 m/z
([(h6-indan)RuCl(m-2,3-dpp)]+). There are also two sets of peaks
with slightly lowerm/z than the molecular ion at 363.51m/z and
353.00 m/z that can be attributed to aquation of 1 and show the
loss of at least one Cl ion. In summary, the mass spectra of
dark solutions of 1 show evidence for aquation and the loss of
chloride ligands and fragmentation into mononuclear species.
However, no loss of an indane ligand from the ruthenium was
detected (Fig. 2A).
A 250 mM solution of 1 in DDW was irradiated with 488 nm
light (5 mW) for 14 h in a cuvette and the resulting spectrum is
shown in Fig. 2B. The intensities of the peaks assignable to
aquated 1 are higher in the spectrum of the irradiated solution
that for the complex in the dark. Peaks for the species at 227.04
m/z assigned to the mononuclear complex [(h6-indan)Ru(2,3-
dpp)]2+ are more intense. The major diﬀerence in the spectra is
the peak at 276.99 m/z that is observed aer irradiation and isFig. 3 (A and B) PCF-MS of 250 mM 1 and 500 mM 50-GMP in DDW. Spect
2,3-dpp) + 50-GMP]2+, the species at 582.03 m/z is [(h6-indan)Ru + 50-G
PCF ﬂow reactor, new peaks 640.04 m/z and 649.04 m/z (shown in inse
indan)Ru2(m-2,3-dpp) + 2(50-GMP) + H2O]
2+, respectively. (C and D) PC
solution, a peak is detected at 348.07m/z ([50-AMP + H]+), and spectrum
new peak at 566.04 m/z (shown in inset) is assigned as [(h6-indan)Ru +
37344 | RSC Adv., 2017, 7, 37340–37348assigned as [(h6-indan)Ru2(m-2,3-dpp)]
2+. This is signicant as it
shows the loss of an indane ligand from 1 and provides
a marker for the photodecomposition of the complex, since
arene loss is not observed under dark conditions. Suggested
structures for these fragments are shown in Table S1 in the
ESI.†
The experiment was then repeated in the integrated PCF-MS
system. The dark spectrum in Fig. 2C shows that the only
diﬀerence from the control experiment in Fig. 2A is an increase
of species resulting from aquation at 363.51 m/z. This is to be
expected as the compound in Fig. 2A had been in solution for
a longer period of time as it was irradiated for longer. There is
also a drop in overall intensities of peaks for the PCF-spectrum,
which is to be expected when a reaction is transferred to the
integrated system, as well as loss of intensity due to hydrolysis
of the initial species. The intensity of the species [(h6-indan)
Ru(2,3-dpp)]2+ (227.04 m/z) is higher for the sample injected in
the dark in the PCF experiment than when directly infused inrum (A) dark solution peak at 517.6m/z assigned as [{(h6-indan)Ru}2(m-
MP]+, and spectrum (B) is after 12 s of irradiation at 488 nm in the HC-
t) are assigned as [(h6-indan)Ru2(m-2,3-dpp) + 2(50-GMP)]
2+ and [(h6-
F-MS of 250 mM 1 and 500 mM 50-AMP in DDW. Spectrum (C) dark
(D) is after 12 s of irradiation at 488 nm in the HC-PCF ﬂow reactor, the
(50-AMP)]+.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinethe dark. The mass spectrum of the irradiated PCF sample in
Fig. 2D displays the same species as the irradiated control in
Fig. 2B, including a signicant increase in the peak at 227.04m/
z, illustrating that the PCF system does not aﬀect the course of
the reaction taking place.
Metal-based anticancer drugs that are currently in the clinic
are known to bind to DNA.34–36 The DNA binding properties of 1
were modelled by irradiating it in the presence of two nucleo-
bases with the most electron-dense donor sites (50-GMP and 50-
AMP). Initially two molar equivalents of 50-GMP were added to
an aqueous solution of 1 (500 mM nucleobase and 250 mM of
complex). Spectra in the dark were obtained for both PCF-MS
and conventional experiments. The samples were irradiated as
follows: 14 h at 5 mW in a cuvette for the conventional
measurement and 12 s during transfer through the PCF
microreactor. The resulting data are summarized in Fig. 3. Once
again there was close agreement between the conventionalFig. 4 (A and B) PCF-MS for the reaction of 250 mM 1 and 500 mM L-Cys
after 15 min irradiation with 488 nm light (5 mW) in a cuvette. The new
[(h6-indan)Ru2(m-2,3-dpp) + 2(L-Cys)]
2+ and 574.09m/z, [(h6-indan)Ru(m-
DDW. Spectrum (C) is from the solution in the dark, with peaks 208.09m/
after 12 s of irradiation at 488 nm in the HC-PCF ﬂow reactor, peaks at 43
[(h6-indan)Ru2(m-2,3-dpp) + GSH]
2+, [(h6-indan)Ru + GSH]+ and [(h6-ind
This journal is © The Royal Society of Chemistry 2017method and the PCF-MS experiment, the only diﬀerences being
a drop in peak intensity for the PCF experiments and the
appearance of the species at 658.6 m/z in only the spectrum
from the PCF irradiated sample.
In the dark spectrum in Fig. 3A, there is the appearance of
a new peak at 517.6m/z [{(h6-indan)Ru}2(m-2,3-dpp) + 50-GMP]
2+.
This suggests that 50-GMP binds to 1 in the dark, probably aer
aquation. This species appears to be fragmented in the mass
spectrometer, giving rise to the ion at 582.03 m/z. Upon irradi-
ation by conventional and PCF-MS methods new peaks were
observed at 458.51m/z and 467.5 2m/z that are assigned as [(h6-
indan)Ru2(m-2,3-dpp) + 50-GMP]
2+ and [(h6-indan)Ru2(m-2,3-
dpp) + 50-GMP + H2O]
2+ (see Fig. 3B). These species are indica-
tive of post-irradiation binding due to the loss of an indan ring.
This conclusion is further supported by the presence of a small
peak at 640.04 m/z, corresponding to a doubly-charged species
assigned as [(h6-indan)Ru2(m-2,3-dpp) + 2(50-GMP)]
2+ and atin DDW. Spectrum (A) is for the solution in the dark and spectrum (B) is
peaks in spectrum (B) are assigned as 396.52 m/z (shown in inset),
2,3-dpp) + (L-Cys)]+. (C and D) PCF-MS of 250 mM 1 and 500 mMGSH in
z assigned as [GSH+H]+, 615.17m/z as [2GSH+H]+ and spectrum (D) is
0.52m/z, 526.06m/z (shown in inset) and 584.06m/z are assigned to
an)Ru2(m-2,3-dpp) + 2GSH]
2+, respectively.
RSC Adv., 2017, 7, 37340–37348 | 37345
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
Ju
ly
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
1/
10
/2
01
7 
16
:4
4:
59
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online649.04 m/z, assigned as [(h6-indan)Ru2(m-2,3-dpp) + 2(50-GMP) +
H2O]
2+. The species at 658.6m/z is present only in the PCF mass
spectrum and is of relatively low intensity; this is assigned as
[(h6-indan)Ru2(m-2,3-dpp) + 2(50-GMP) + H2O + 2H
+]2+. The
binding of 50-GMP that occurs aer aquation of the complex
also increases in the post-irradiation spectra.
Complex 1 was then irradiated in the presence of 50-AMP
under the same conditions as those for 50-GMP (250 mM 1 and
500 mM nucleobase). In the dark there appeared to be no reac-
tion between 1 and 50-AMP, see Fig. 3C. Aer irradiation by both
methods, a species appeared at 623.55 m/z; this is assigned as
[(h6-indan)Ru2(m-2,3-dpp) + 2(50-AMP)]
2+ (Fig. 3B and D). The
low intensity of this peak in the PCF-MS spectrum and low
signal-to-noise ratio did not allow this peak to be assigned
based on these data alone. However, the assignment was
conrmed using the sample irradiated by conventional
methods. This was also the case for the peak at 566.04 m/z,
assigned as [(h6-indan)Ru + (50-AMP)]+.
To study the interaction with amino acids, complex 1 was
irradiated in the presence of L-cysteine at a molar ratio of 2 : 1
(500 mM amino acid, 250 mM complex). The PCF-MS sample
was incubated at ambient temperature for 30 min in the dark,
and 14 h for the conventional measurement. There appeared
to be no reaction in the dark between 1 and L-cysteine, see
Fig. 4A.
Upon irradiation by both conventional and PCF-MS
methods a series of peaks appeared at 337–339 m/z. These
are doubly charged ions and, from their isotopic pattern,
contain more than one Ru atom. These species are likely to be
[(h6-indan)Ru2(m-2,3-dpp) + (L-Cys)]
2+, 338.49 m/z and [Ru2(m-
2,3-dpp) + 2(L-Cys)]2+, 339.99m/z. However, the low intensity of
the signals and overlap meant that these assignments were
diﬃcult to conrm. Two other photoproducts were also
detected and are shown in Fig. 4B. These are [(h6-indan)Ru(m-
2,3-dpp) + (L-Cys)]+, 574.09 m/z, and [(h6-indan)Ru2(m-2,3-dpp)
+ 2(L-Cys)]2+ at 396.52 m/z.
Reactions with the tripeptide glutathione (g-L-Glu-L-Cys-Gly,
GSH) were studied since this tripeptide oen plays an impor-
tant role in the cellular mechanism of resistance to metal-based
drugs.37–39 Complex 1 (250 mM) was irradiated in the presence of
two molar equiv. glutathione (GSH), see Fig. 4B and D, with the
dark controls again incubated for the same length of time as the
period of irradiation (30 min for the PCF-MS experiments and
14 h for the sample analysed conventionally). The dark control
shows a new species at 408.56m/z that contains one Ru atom, is
doubly charged, and appears to contain one molecule of GSH
and a fragment of GSH bound with the loss of an indan group.
This species was present even in the dark but its intensity
decreased aer irradiation. In the spectrum of the irradiated
reaction more new species were observed including that at
430.52 m/z assigned as [(h6-indan)Ru2(m-2,3-dpp) + GSH]
2+, and
526.06 m/z as [(h6-indan)Ru + GSH]+. Species at around 580 and
584 m/z form a cluster of peaks in the PCF-MS spectrum
(Fig. 4D), but in the spectrum of the conventionally irradiated
sample only the 584.06 m/z species, [(h6-indan)Ru2(m-2,3-dpp) +
2GSH]2+ is present.37346 | RSC Adv., 2017, 7, 37340–37348Conclusions
Hollow-core photonic crystal bre microreactors oﬀer an inte-
grated technique for the analysis of photochemical reactions.
The combination of a low-volumemicrouidic, continuous ow
circuitry with high optical intensities in the HC-PCF renders the
approach much less sample- and time-consuming than cuvette-
based analytical approaches. This novel technique has been
used here to gain new insight into reactions of potential
importance to the biological mechanism of action of the
dinuclear ruthenium(II) complex 1, [{(h6-indan)RuCl}2(m-2,3-
dpp)](PF6)2. Complex 1 was used for exploratory PCF-MS studies
as it is a positively-charged photoactivatable metal complex with
potential to form novel adducts with biomolecules and so
introduce a new mechanism of metallodrug action. The
compound gave a highMS signal intensity when owed through
the system and unambiguous assignment of photoproducts
from the complex was readily achieved. The spectra from PCF-
MS experiments and controls based on conventional irradia-
tion methods showed no diﬀerences other than a small reduc-
tion in intensity of peaks for the PCF-MS spectra. All the
detected species were the same by both methods. However, the
time needed for sample irradiation and the total sample volume
was dramatically reduced by using the PCF-MSmethod, from 14
hours to 12 seconds (the residence time in the HC-PCF core).
Upon irradiation of 1, by bothmethods, there was an increase in
the species at 227.04 m/z assigned as [(h6-indan)Ru(2,3-dpp)]2+,
suggesting that exposure to light can result in new reaction
pathways, including loss of an arene ligand.
Having established the suitability of the PCF-MS system to
study the irradiation of 1, a series of experiments using a range
of small molecules to act as models for larger species present
within cells was carried out to gain insight into reactions that
might be relevant to its biological activity. Guanine N7 is oen
a favoured binding site for metal-based drugs, and in the
presence of the nucleotide guanosine 50-monophosphate, 50-
GMP,35,36 1 undergoes aquation and forms a mono-adduct. This
is supported by the ndings of Magennis et al. who reported
DNA binding of 1 in the dark.33 When 1 was irradiated in the
presence of 50-GMP, new 50-GMP adducts were detected. The
binding of 50-GMP that occurs following aquation of the
complex also increases in the post-irradiation period.
Similarly, when photoactivated in the presence of 50-AMP,
adducts of 50-AMP with 1 were also detected, but the peaks
attributed to these are less intense than products formed by 50-
GMP. Magennis et al. also reported an increase in DNA binding
upon irradiation.33
The reaction of 1 with L-Cys is consistent with the ndings of
Wang et al. who reported that [(h6-biphenyl)Ru (en)Cl]+ reacts
slowly with L-cysteine in aqueous solution.5 Complex 1 also
binds to the cysteine-containing tripeptide glutathione, which
is present in cells at millimolar concentrations, as indicated by
the detection of the peaks at 430.52 m/z, 526.06 m/z and 584.06
m/z assignable to [(h6-indan)Ru2(m-2,3-dpp) + GSH]
2+, [(h6-
indan)Ru + GSH]+ and [(h6-indan)Ru2(m-2,3-dpp) + 2GSH]
2+
respectively. Binding to GSH following photoactivation of 1mayThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineinuence its biological activity. Hence these experiments
suggest that this PCF-MS system will be useful as a high-
throughput method of screening for light-activated drugs,
providing insight into reactions of importance to drug design
and activity.
Several improvements to our current system can be envis-
aged: rstly, the overall time for data acquisition could be
minimized by reducing the internal dead volume of the HR-MS,
for instance by electrospray ionisation directly from the opto-
uidic interface chip.40–42 This would allow the detection of
(even) shorter-lived reaction species that are undetectable using
conventional techniques. In addition, the current system could
be combined with in-bre spectroscopic methods.25 This would
allow simultaneous excitation, optical detection and mass-
spectrometry analysis of reaction products. Finally, we foresee
that our approach can be combined with other lab-on-a-chip
functionalities40,43 for sample preparation, separation and
(multimodal) analysis in a straightforward fashion. In such an
integrated system, laser light could be delivered by bre-to-bre
coupling between the HC-PCF and embedded standard optical
bres, allowing easy operation without alignment of optical
components.
Finally, we have used blue light in the current studies, but
longer wavelength light penetrates more deeply into tissues. It
would therefore be interesting to use our system to probe the
metallodrugs that are optimised for excitation at longer wave-
lengths. An alternative strategy would be to employ a two-
photon excitation process, using e.g. pulsed 800 nm wave-
length light to achieve activation at 400 nm. Liquid-lled HC-
PCFs could be used to study and optimise such nonlinear
processes, as we recently demonstrated for two-photon excita-
tion of uorescein in a HC-PCF.44Conﬂict of interest
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